HomeAboutMediaCareersSite MapContactSearch
Geron
merck,telomerase vaccine
PatientsProductsTechnology & ScienceInvestors
print
  • About Geron
    • Executive Management
    • Board of Directors
    • Contact Information
  • Affiliates
    • Geron Bio-Med Ltd
    • TA Therapeutics
  • Licensees
    • ViaGen
    • Merck
    • Roche
    • Sienna
    • Cell Genesys
  • Directions to Geron

Merck

In July 2005, we entered into a worldwide exclusive research, development and commercialization license agreement with Merck & Co. (Merck), Inc. for cancer vaccines targeting telomerase by methods other than dendritic cell delivery. In addition, Merck acquired an exclusive option to negotiate a separate agreement for our autologous dendritic cell-based telomerase vaccine. On December 31, 2007, Merck's option to our dendritic cell-based vaccine technology expired and Geron retains all product rights for all indications using both autologous and hESC-derived dendritic cells. In December 2007, Merck filed an IND to initiate a clinical trial for their cancer vaccine candidate that targets telomerase.

Visionary Therapeutics
Home | About | Media | Careers | Site Map | Contact | Search
Patients | Products | Technology & Science | Investors
Legal Disclaimer
Copyright © Geron 2008. All rights reserved.
Site design and layout by BFW Interactive